Table 1 Study subject demographics
Demographic characteristic | Combination therapy study: utidelone (30 mg/m2) and capecitabine (2000 mg/m2) n = 33 | Monotherapy study: utidelone (40 mg/m2) n = 70 | |
|---|---|---|---|
Age (year) | Median | 50 | 51 |
Range | 28–66 | 31–71 | |
Sex, n (%) | Female | 33 (100) | 70 (100) |
ECOG PS, n (%) | 0 | 19 (57.6) | 9 (12.9) |
1 | 14 (42.4) | 60 (85.7) | |
2 | 0 (0.0) | 1 (1.4) | |
Clinical stage, n (%) | IV | 33 (100) | 70 (100) |
Metastasis site, n (%) | ≤2 | 20 (60.6) | 47 (67.1) |
>2 | 13 (39.4) | 23 (32.9) | |
Number of target lesions, n (%) | 1 | 18 (54.5) | 39 (55.7) |
2 | 10 (30.3) | 18 (25.7) | |
>2 | 5 (15.2) | 13 (18.6) | |
Past chemotherapy courses, n (%) | 1 | 6 (18.2) | 10 (14.3)a |
2 | 12 (36.4) | 20 (28.6) | |
3 or more | 15 (45.5) | 40 (57.1) | |
Past treatment regimens containing, n (%) | Anthracyclines | 33 (100) | 67 (95.7) |
Taxanes | 30 (90.9) | 67 (95.7) | |
Taxanes + anthracyclines | 27 (81.8) | 64 (91.4) | |
Capecitabine | 13 (39.4) | 34 (48.6) | |
Taxanes + anthracyclines + capecitabine | 11 (33.3) | 33 (47.1) | |
Concurrent diseases or complications, n (%) | No | 30 (90.0) | 54(77.1) |
Yes | 3 (9.1) | 16(22.9) | |
Primary tumor excised, n (%) | Yes | 32(97.0) | 68(97.1) |
Received radiation therapy, n (%) | Yes | 18(57.6) | 48 (68.6) |